Holen Sie sich die Stockscreener-App
36.80
13.02%
4.24
Handel nachbörslich:
37.10
0.30
+0.82%
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Enterprise value to revenue forward of Neurogene Inc. – NASDAQ:NGNE - TradingView
Neurogene prices $125M equity offering - MSN
Neurogene announces pricing of $125 million public offering - The Pharma Letter
Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com
Neurogene president and CFO Cvijic sells $166,586 of company stock By Investing.com - Investing.com India
Form 4 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan - Stock Titan
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene Nets ~$135 Million From Equity Offering; Underwriters Exercise Full Option - TradingView
Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada
Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com South Africa
Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal - Stock Titan
Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView
Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Australia
Neurogene prices $125 million public offering at $30 per share - Investing.com
Neurogene Sets Pricing For $125 Million Public Offering - TradingView
Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada
Neurogene Prices $125 Million Public Offering - marketscreener.com
Neurogene locks in $125M stock sale, closing expected July 2 - Stock Titan
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett SyndromeSlideshow - Seeking Alpha
Form 424B5 Neurogene Inc For: 30 June - Investing.com UK
Neurogene launches public offering of common stock By Investing.com - Investing.com South Africa
Neurogene to Sell Shares in Secondary Offering - Moomoo
Neurogene prices $125M public offering at $30/share - scanx.trade
Form 424B5 Neurogene Inc For: 30 June By Investing.com - Investing.com Australia
Neurogene stock falls on public offering announcement - Investing.com UK
Neurogene stock falls on public offering announcement By Investing.com - Investing.com South Africa
Neurogene launches public stock offering - MSN
Neurogene Inc Files For Offering Of Common Stock, Pre-Funded Warrants To Buy Common Stock Size Not DisclosedSEC Filing - TradingView
Neurogene Launches Public Offering - marketscreener.com
Neurogene Inc. (NGNE) files to offer common stock and pre-funded warrants - Stock Titan
Neurogene launches public offering of common stock - Investing.com
Neurogene Inc. Announces Proposed Public Offering - TradingView
Neurogene seeks new funding for NGN-401 development - Stock Titan
Canaccord reiterates Neurogene stock rating on Rett syndrome data - Investing.com UK
Guggenheim Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $69 - Moomoo
H.C. Wainwright reiterates Neurogene stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Neurogene stock rating on trial data By Investing.com - Investing.com South Africa
Canaccord reiterates Neurogene stock rating on Rett syndrome data By Investing.com - Investing.com Nigeria
Neurogene reports 47 milestone gains in NGN-401 trial - grafa.com
Neurogene reports milestone gains in Rett syndrome gene therapy trial By Investing.com - Investing.com India
$32.506 | Neurogene Inc. Common Stock (NGNE) Stock Price Today - Binance
Neurogene reports promising long-term NGN-401 Rett data - TipRanks
Neurogene reports durable Phase 1/2 NGN-401 gains: 47 milestones across 10 patients, Embolden topline due 2H 2027 - TradingView
Rett gains: Neurogene (NASDAQ: NGNE) shows durable NGN-401 milestone data - Stock Titan
Neurogene Says Phase 1/2 NGN-401 Data Show Progressive Improvements in Rett Syndrome - marketscreener.com
Neurogene (NGNE) Reports Positive Phase 1/2 Trial Results for NG - GuruFocus
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):